Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2021-10-21 Earnings Release
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT ON THE UNAUDITED MAJOR OPERATIONAL DATA OF THE THIRD QUARTER OF 2021
Earnings Release Classification · 90% confidence The document is an announcement titled 'ANNOUNCEMENT ON THE UNAUDITED MAJOR OPERATIONAL DATA OF THE THIRD QUARTER OF 2021' by Yanzhou Coal Mining Company Limited. It provides unaudited operational data for the third quarter of 2021 and the first three quarters of 2021, including production and sales volumes for coal and coal chemicals. The data is described as unaudited and is explicitly stated to be different from the company's interim and annual reports. The document is relatively short (4632 characters) and is an announcement of operational data rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). It is a voluntary announcement providing key operational metrics for a quarter, which aligns with the category of Earnings Release (ER) as it highlights key quarterly operational results without full financial statements. Therefore, the best classification is Earnings Release (ER). Q3 2021
2021-10-21 English
POSITIVE PROFIT ALERT FOR THE FIRST THREE QUARTERS OF 2021
Earnings Release Classification · 95% confidence The document is a profit alert announcement for the first three quarters of 2021 by Yanzhou Coal Mining Company Limited. It provides estimated financial results for the period from January 1, 2021 to September 30, 2021, including net profit and earnings per share, but explicitly states that these results are preliminary and unaudited. It also mentions that detailed and accurate financial information will be provided in the formally disclosed third quarter report. The document is an announcement of estimated financial performance rather than a full interim or quarterly report containing actual financial statements and substantive analysis. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. 9M 2021
2021-10-21 English
VOLUNTARY ANNOUNCEMENT - CSTONE RECEIVED CHINA NMPA IND ACCEPTANCE FOR LORLATINIB IN CHINESE PATIENTS WITH ROS1-POSITIVE ADVANCED NSCLC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the acceptance of an Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for lorlatinib in Chinese patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). It discusses clinical study plans, drug background, strategic partnerships, and company information. There are no financial statements, quarterly or annual results, or detailed financial data. The document is an announcement of a regulatory milestone related to drug development, not a financial report or management discussion. It is not a report publication announcement since it contains substantive information about the IND acceptance and clinical plans. The content fits best under a general regulatory announcement category related to compliance and regulatory updates. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-10-20 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-10-19 English
PUBLICATION OF THE PRODUCTION AND SALES VOLUME FOR THE THIRD QUARTER OF 2021 OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANZHOU COAL MINING COMPANY LIMITED
Regulatory Filings Classification · 95% confidence The document is a short announcement (2509 characters) from Yanzhou Coal Mining Company Limited regarding the production and sales volume for the third quarter of 2021 of an overseas subsidiary, Yancoal Australia. It provides summary data for production and sales volumes but does not contain detailed financial statements or comprehensive analysis. It also refers readers to the full reports published by Yancoal Australia on the ASX and HKEX websites for further details. The document is clearly an announcement of operational data rather than a full financial report or detailed investor presentation. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories. It is not an earnings release (ER) because it lacks key financial highlights or earnings figures, nor is it a full interim or quarterly report (IR) because it lacks substantive financial data and analysis. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-10-19 English
NOTIFICATION OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a notice of a board meeting scheduled to consider the publication of the unaudited third quarterly results for the period ended 30 September 2021. It is an announcement about the meeting and the upcoming financial results, not the financial report itself. The document length is short (1671 characters) and it does not contain any actual financial data or detailed financial statements. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) announcing the board meeting and the upcoming results publication.
2021-10-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.